TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33063141
Drug: Bi-monthly questionnaires
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi-monthly questionnaires covering SARS-CoV-2 symptoms, health, preventive behavior, and lifestyle information.
Study: 33063185
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg doxorubicin (DOX) and 10 mg mitomycin C emulsified 1:2 with ethiodized oil (Lipiodol) during conventional transarterial chemoembolization (cTACE)
Study: 33064988
Drug: Personalized neoantigen-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized neoantigen-based vaccine NEO-PV-01 plus PD-1 blockade
Study: 39187749
Drug: Chronic migraine
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic migraine with medication overuse (CM-MO)
Study: 33066794
Drug: One-month dual-antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-month dual-antiplatelet therapy (DAPT) followed by 23-month ticagrelor monotherapy
Study: 33066794
Drug: 12-month DAPT
Normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month DAPT followed by 12-month aspirin alone
Study: 33067297
Drug: CC-1 bispecific
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-1 bispecific PSMAxCD3 antibody administered after prophylactic interleukin-6 receptor blockade with tocilizumab (8 mg/kg body weight).
Study: 33067318
Drug: KTE-X19, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: KTE-X19, an autologous anti-CD19 CAR T-cell therapy
Study: 33067633
Drug: BAX 335
Normalized name: BAX 335
DrugBank: BAX 335 (DB17845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX 335 gene therapy (1 of 3 IV doses: 2.0 × 10^11; 1.0 × 10^12; or 3.0 × 10^12 vector genomes/kg)
Study: 33067633
Drug: BAX 335
Normalized name: BAX 335
DrugBank: BAX 335 (DB17845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAX 335 gene therapy
Study: 33068284
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally for 4 weeks followed by 2 weeks off)
Study: 33068794
Drug: Ramucirumab 10
Normalized name: ramucirumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 10 mg/kg and Pembrolizumab 200 mg every 21 days for up to 35 cycles
Study: 33069648
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of factors (Evolut TAV, TAV-sinus of Valsalva relation, implantation depth)
Study: 33070260
Drug: sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab (200 mg) plus chemotherapy (pemetrexed 500 mg/m2)
Study: 33070964
Drug: Highest quintile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quintile of fasting glucose (≥5.1 mmol/L)
Study: 33070964
Drug: Highest 2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest 2-hour postload glucose quintile (≥6.9 mmol/L)
Study: 33071013
Drug: Urinary 3-hydroxyisovaleryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urinary 3-hydroxyisovaleryl carnitine (3-HIC) excretion
Study: 33072090
Drug: Polymyxin B
Normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polymyxin B (bactericidal antibiotic)
Study: 33072090
Drug: Clodronate (macrophage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (macrophage modulator)
Study: 33072399
Drug: Chimeric antigen
Normalized name: Chimeric antigen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy)
Study: 33072814
Drug: Prolonged low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolonged low-dose methylprednisolone (MP)
Study: 33073219
Drug: rBCG-N-RSV vaccine
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: rBCG-N-RSV vaccine
Study: 33073527
Drug: Bevacizumab plus
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab plus original chemotherapy regimen
Study: 33073527
Drug: Original chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original chemotherapy regimen
Study: 33073614
Drug: S-ICD implant
Normalized name: Synovex S Drug Implant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ICD implant
Study: 33074373
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection or vitreoretinal surgery with incision distance of 3.5-4.0 mm posterior to the limbus.
Study: 33074401
Drug: Osilodrostat 10
Normalized name: osilodrostat 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osilodrostat 10 mg twice daily
Study: 33074406
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of opioids and sedatives
Study: 33074941
Drug: Maintenance fluids,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance fluids, nutritional fluids, drug fluids
Study: 33074941
Drug: Diuretics or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics or renal replacement therapy
Study: 33074941
Drug: Sodium administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium administration
Study: 33074941
Drug: Potassium administration
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium administration
Study: 33075126
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) in ACS patients
Study: 33075126
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (SAPT) in ACS patients
Study: 33075126
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) in SIHD patients
Study: 33075126
Drug: Single antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single antiplatelet therapy (SAPT) in SIHD patients
Study: 33075159
Drug: Oral repaglinide
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral repaglinide
Study: 33075159
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin glargine
Study: 33076864
Drug: Ziv-aflibercept intravitreal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziv-aflibercept intravitreal injection
Study: 34320504
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA) treatment
Study: 33077867
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (IC)
Study: 33077867
Drug: Non-intensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-intensive treatment
Study: 33077867
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (IC) in 2007-2013 vs 1999-2006
Study: 33078373
Drug: Formalin fixation
Normalized name: formalin
DrugBank: Formaldehyde (DB03843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formalin fixation of tumor specimens after infusion of panitumumab-IRDye800CW (25 or 50 mg)
Study: 33080003
Drug: CD8+ T
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS, ENRICHED FROM PERIPHERAL BLOOD MONONUCLEAR CELLS (PBMCS) TRANSDUCED WITH A NONREPLICATIVE SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR ENCODING A CHIMERIC ANTIGEN RECEPTOR (CAR) CONSISTING OF THE HUMAN CD19-SPECIFIC SCFV
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD8+ T cells and their cytotoxic effector molecules
Study: 33080911
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab Emtansine (T-DM1) as second-line therapy
Study: 33080911
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab Emtansine (T-DM1) as third-line therapy
Study: 33080911
Drug: Trastuzumab Emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trastuzumab Emtansine (T-DM1) as fourth-line therapy or higher
Study: 33082372
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) therapy, duration shortened in 11 of the 29 patients (38%)
Study: 33083026
Drug: Ad26 vector-based
Normalized name: SARS-COV-2 (COVID-19) vaccine, vector - Ad26
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ad26 vector-based vaccine (Ad26.COV2.S)
Study: 33083561
Drug: Metformin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin as adjunctive therapy
Study: 33083661
Drug: Proton Beam
Normalized name: Beam
DrugBank: Tricyclazole (DB02891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Beam Therapy (PBT) reirradiation
Study: 33083685
Drug: Remote, real-time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote, real-time activity-monitoring devices combined with daily electronic patient-reported outcome (ePRO) items.
Study: 33083685
Drug: Standard HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HF assessment (e.g., 6-min walking distance [6MWD], blood biomarkers, Kansas City Cardiomyopathy Questionnaire [KCCQ], and echocardiography).
Study: 33083853
Drug: Passeo-18 lx
Normalized name: LX-7101
DrugBank: LX-7101 (DB16009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passeo-18 lx drug-coated balloon
Study: 33084880
Drug: Torasemide, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Torasemide, 5 mg daily for 16 weeks
Study: 33084880
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (G allele)
Study: 33085815
Drug: C-type lectin
Normalized name: An autologous chimeric antigen receptor (CAR) T-cell therapy engineered to express an antibody-derived single-chain variable fragment that recognizes C-type lectin-like molecule-1 (CLL-1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-type lectin receptors (CLRs)
Study: 33087142
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation with a fractionated marine lipid concentration standardized to 17-HDHA and 18-HEPE for 4 weeks
Study: 33087333
Drug: Camrelizumab 200
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Camrelizumab 200 mg (for bodyweight ≥50 kg) or 3 mg/kg (for bodyweight <50 kg) every 2 weeks plus oral apatinib 250 mg daily
Study: 33087345
Drug: nTreg infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: nTreg infusion (0.5, 1.0, or 2.5-3.0×10^6 cells)
Study: 33087345
Drug: Reference group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference group (standard dual or triple drug immunosuppression)
Study: 33087548
Drug: Low-dose CT
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CT lung cancer screening (LDCT)
Study: 33088573
Drug: PBMT-sMF (photobiomodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT-sMF (photobiomodulation therapy combined with static magnetic field)
Study: 33089005
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release transdermal nicotine
Study: 33089304
Drug: CDR132L (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDR132L (monthly intravenous treatments over 3 or 5 months)
Study: 33089593
Drug: 8 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 weeks of treatment for bipolar disorder
Study: 33090333
Drug: Cetuximab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (loading dose followed by weekly infusions of 250 mg/m2)
Study: 33090368
Drug: Pregabalin treatment
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin treatment in FM patients.
Study: 33091124
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood (CB)-derived adoptive cell therapy after salvage chemotherapy
Study: 33091124
Drug: Cord blood
Normalized name: CORD BLOOD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cord blood (CB)-derived adoptive cell therapy
Study: 39252018
Drug: Medication for
Normalized name: SALICYLIC ACID 10 mg in 1 mL TOPICAL LOTION [Serious Skincare Continuously Clear Acne Medication For Problematic skin Dry Lo Pro All- Over Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication for opioid use disorder (MOUD)
Study: 33091842
Drug: Safer opioid
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safer opioid analgesic prescribing
Study: 33092403
Drug: Ibrutinib treatment
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib treatment for 4 weeks
Study: 33092403
Drug: Acalabrutinib treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib treatment for 4 weeks
Study: 33092403
Drug: Kinase inhibitors
Normalized name: PROTEIN KINASE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinase inhibitors blocking Csk
Study: 33092438
Drug: hs-CRP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: hs-CRP level <1.0 mg/L
Study: 33092646
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment including Very Low Energy Diet (VLED)
Study: 34966107
Drug: Imlifidase treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imlifidase treatment
Study: 33093900
Drug: Intravitreal administration
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal administration of bevacizumab (Lumiere)
Study: 33094474
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy (400 mg/day)
Study: 33094474
Drug: Venetoclax plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax plus rituximab (400 mg/day)
Study: 33095117
Drug: Fludarabine-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine-based therapies
Study: 33095117
Drug: C/CHOP-based therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/CHOP-based therapies
Study: 33095117
Drug: Chlorambucil-based therapy
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil-based therapy
Study: 33095117
Drug: Novel therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel therapies (kinase inhibitors)
Study: 33095287
Drug: Crizotinib at
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib at 215 mg/m² in combination with cyclophosphamide and topotecan
Study: 33095287
Drug: Crizotinib at
Normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crizotinib at 165 mg/m² and 280 mg/m²
Study: 33095411
Drug: XC8 2
Normalized name: Cefuroxime
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: XC8 2 mg
Study: 33095411
Drug: XC8 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 10 mg
Study: 33095411
Drug: XC8 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 100 mg
Study: 33095874
Drug: Unlabeled daratumumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unlabeled daratumumab (0 mg, 10 mg, 45 mg, 95 mg)
Study: 37556023
Drug: Lurbinectedin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin 3.2 mg/m²
Study: 33096476
Drug: Chemo-radiation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo-radiation treatment
Study: 33097612
Drug: Emactuzumab (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emactuzumab (500 to 1000 mg) and Selicrelumab (2 to 16 mg) administered intravenously every 3 weeks
Study: 33097687
Drug: Belantamab mafodotin
Normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belantamab mafodotin (3.4 mg/kg, every 3 weeks)
Study: 33098195
Drug: Neoadjuvant carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant carboplatin (AUC 6) every 28 days for four cycles plus nab-paclitaxel (100 mg/m2)
Study: 33099491
Drug: Isotoxic hypofractionated
Normalized name: ISOTON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotoxic hypofractionated concurrent chemoradiotherapy with docetaxel plus lobaplatin
Study: 33099678
Drug: arfolitixorin (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: arfolitixorin (at four dose levels)
Study: 33099742
Drug: Lobeglitazone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobeglitazone (0.5 mg for 24 weeks)
Study: 33099742
Drug: Pioglitazone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15 mg for 24 weeks)
Study: 33100036
Drug: LVAD support
Approvals — FDA: no, EMA: no, PMDA: no
Description: LVAD support combined with standardized pharmacological therapy and cardiac function monitoring protocol
Study: 33101027
Drug: Patch containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch containing Allium cepa and allantoin
Study: 33101027
Drug: Patch containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch containing Allium cepa and allantoin (Group B)
Study: 33101079
Drug: Probiotics (De
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (De Simone Formulation)
Study: 33101409
Drug: SHBG <26.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHBG <26.75 mmol/L
Study: 33102224
Drug: Concurrent radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent radiotherapy and systemic therapy, specific details not available.
Study: 33102510
Drug: Fermented whey
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented whey concentrate (FWC) drink rich in L-(+)-Lactic acid, consumed daily
Study: 33103032
Drug: 150-mg once-monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150-mg once-monthly risedronate
Study: 33104796
Drug: Ruxolitinib 25
Normalized name: ruxolitinib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 25 mg twice daily for induction, followed by 10 mg twice daily for subsequent cycles, combined with decitabine 20 mg/m2 for 5 consecutive days in a 28-day cycle.
Study: 33104796
Drug: Ruxolitinib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib and decitabine combination treatment.
Study: 33105385
Drug: Sildenafil treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil treatment for 4 weeks
Study: 33106665
Drug: Precision medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision medicine treatment based on prospective genomic profiling
Study: 33107983
Drug: Crenigacestat (LY3039478)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crenigacestat (LY3039478) at 50 mg, 75 mg, 100 mg, and 125 mg orally 3 times per week plus dexamethasone at 24 mg twice daily on days 1 to 5 every other week in a 28-day cycle.
Study: 33108270
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) treatment with ≥6-hour use
Study: 33108270
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) treatment with ≥4-hour use
Study: 33108543
Drug: Elagolix 200
Normalized name: elagolix 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elagolix 200 mg twice daily
Study: 33109505
Drug: Juice intake
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Juice intake (8 oz daily)
Study: 33109505
Drug: Water/Sugar-Free Beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water/Sugar-Free Beverage (SFB) intake (8 oz daily)
Study: 33109505
Drug: Sugar-Sweetened Beverages
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-Sweetened Beverages (SSB) intake (8 oz daily)
Study: 33109505
Drug: Toothbrushing (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothbrushing (additional daily event)
Study: 33109627
Drug: Ribociclib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ribociclib and letrozole (400 mg of ribociclib and 2.5 mg of letrozole daily)
Study: 33110622
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cholecalciferol (1600 IU/day for < 1 year, 2400 IU/day for > 1 year)
Study: 33112242
Drug: ePRO follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: ePRO follow-up using a weekly questionnaire evaluating symptoms and an urgency algorithm for alerts.
Study: 33113214
Drug: Combined CCNU/TMZ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CCNU/TMZ therapy
Study: 33114652
Drug: Atu027 (0.235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atu027 (0.235 mg/kg twice weekly) + Gemcitabine
Study: 33114652
Drug: Atu027 (0.235
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atu027 (0.235 mg/kg once weekly) + Gemcitabine
Study: 33115374
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg amiselimod
Study: 33115374
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg amiselimod
Study: 33115374
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg and 0.4 mg amiselimod
Study: 33117015
Drug: Interactive Music
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interactive Music Therapy (IMT)
Study: 33117256
Drug: Combined IAMZS
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined IAMZS (20 min) and medication
Study: 33117256
Drug: Sole medication
Normalized name: English sole
DrugBank: English sole (DB10904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sole medication
Study: 33117454
Drug: Dapagliflozin 10
Normalized name: dapagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin 10 mg once daily for one week